secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001193125-25-037586
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viridian reports positive phase 3 data for veligrotug in TED; cash $717.6M
--------------------------------------------------------------------------

- Veligrotug met all primary and secondary endpoints in THRIVE and THRIVE-2 for active and chronic TED.
- BLA submission on track for 2H 2025; MAA submission expected 1H 2026.
- Cash, equivalents, and investments $717.6M as of Dec 31, 2024, funding operations into 2H 2027.
- Net loss $269.9M for 2024 vs $237.7M in 2023; R&D expenses rose to $238.3M.
- Appointed Radhika Tripuraneni as CMO, succeeding Thomas Ciulla who transitions to consultant.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312525037586/0001193125-25-037586-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312525037586/d865236d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-037586

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer